Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Why is Harmony Biosciences Holdings Inc (HRMY) Stock down?

We've noticed a 5.63% decline in Harmony Biosciences Holdings Inc (HRMY) stock during the 2024-04-12 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!

13 Oct, 2023:

Harmony Biosciences Holdings (HRMY) dropped by 30.25% from $30.27 to $21.11 in the trading on Friday October 13, 2023. The reason why HRMY stock down today is due to the topline data from its Phase 3 INTUNE study of its therapy Pitolisant to treat idiopathic hypersomnia (IH). The drug did not meet its primary endpoint of statistically significant decrease on the Epworth Sleepiness Scale (ESS) compared to a placebo, noting no statistically significant difference was observed.

25 Sep, 2023:

Harmony Biosciences Holdings Inc (HRMY) fell 8.68% to $33.13 after Goldman Sachs downgraded the previous rating for the stock from Neutral to Sell.

https://www.benzinga.com/analyst-ratings/upgrades/23/09/34869212/benzingas-top-ratings-upgrades-downgrades-for-september-25-2023

28 Mar, 2023:

Harmony Biosciences' stock (NASDAQ: HRMY) is experiencing a decline in its share value following the submission of a Citizen's Petition to the FDA by Scorpion Capital, which requested the withdrawal of approval of Wakix (pitolisant). Wakix was granted FDA approval for the treatment of excessive daytime sleepiness or cataplexy in adult narcoleptic patients, and has been on the market in the U.S. since the fourth quarter of 2019.

https://finance.yahoo.com/news/short-seller-report-harmony-biosciences-154102274.html